Pet owners and allergy sufferers swear by this Shark air purifier - grab it now on sale for just $134.99 and save even more with this code!
An air purifier can help you breathe easy, especially during allergy season. It can get rid of pollen, dust, dirt, and odors in your space, helping you breathe clean air at all times.
Air purifiers can be expensive though, that's why it's so important to be on the lookout for new deals. One such deal just hit QVC, and the Shark Air Purifier With True HEPA is down to $149.99 right now — a 25 percent discount. You can also get an additional $15 off your order if you're a first-time QVC shopper with code HELLO15.
Shark Air Purifier With True HEPA
Shark says this air purifier can get rid of 99.98 percent of dander, allergens, smoke, and dust.
It's compact and best for small spaces, and features a 4.8-star review from QVC shoppers.
It is down to $149.99 right now — a 25 percent discount. You can also get an additional $15 off your order if you're a first-time QVC shopper with code HELLO15.
$134.99 (was $200) Shop
Shark says this air purifier can get rid of 99.98 percent of dander, allergens, smoke, and dust. It can easily clean up to 500 square feet of space, perfect for small rooms or studios.
It also weighs under six pounds, making it portable, and has a lengthy six-foot cord, so finding an outlet for it shouldn't be a problem.
This Shark air purifier also features Clean Sense IQ, which the brand says automatically senses air quality and makes adjustments to your gadget as needed. If you don't choose auto mode, you can pick between four fan speeds, depending on your preferences.
Another great addition is the easy-to-read LED display up front will let you know how clean or dirty the air in your space is at any given time.
There are timer controls, too, so your air purifier is not working overtime. And, the LED display can be dimmed so it won't disturb you while you sleep at night.
QVC shoppers seem to love this product, giving it a glowing 4.8-star rating.
'I bought two more after receiving one for Christmas. I live on a dirt road and have two shedding dogs. I found having just one in our open area to save me from constant dusting and vacuuming,' says one shopper.
Many others agreed, saying this is a must-have for pet owners.
'This air purifier has exceeded my expectations. It does a great job of keeping odors at bay in my home office, which also houses the litter box. In addition, I love that I can tell what the clean air level is. The filter is also extremely easy to change,' says another.
A ton of reviewers also complimented its ability to get rid of odors and smoke quickly, and prevent allergens from irritating their sinuses.
'I also have allergies to mold and dust, and I breathe noticeably better and easier after this unit has been running continuously for 24 hours a day. Need I mention that I bought another unit after the second week of receiving the first one,' concludes a third.
It really is a game-changer for both pet owners and those that suffer from allergies. Shop it now for 25 percent off and use code HELLO15 to take an additional $15 off your order — you won't be disappointed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
29 minutes ago
- Reuters
TSX futures inch up ahead of key economic data
June 5 (Reuters) - Futures linked to Canada's primary stock index rose slightly on Thursday, as investors awaited economic data from the United States and home to assess the impact of U.S. President Donald Trump's tariffs on the economy and global trade. The S&P/TSX index futures were up 0.2% at 6:35 am ET (1035 GMT). Data scheduled for Thursday are U.S. initial jobless claims and the international trade report at 08:30 a.m. ET. Focus will also be on Friday's employment figures from Canada and non-farm payrolls data from the U.S. to assess the effect of Trump's trade policies on the labour market. Meanwhile, the United States' tariff hike on steel and aluminum took effect on Wednesday. Canada, the largest seller of the metals to the U.S., exports roughly twice as much aluminum as the rest of the top 10 exporters combined. Canadian companies and a major union said higher U.S. tariffs could result in more job losses and lost sales. Prime Minister Mark Carney said Canada is prepared to strike back against the U.S. if talks with Washington to remove tariffs do not succeed. Also on Thursday, China blocked Canada's request to set up a dispute panel to review additional import duties by Beijing on certain Canadian products. Eyes will be on potential negotiations between Washington and its trading partners, with Trump and Chinese leader Xi Jinping expected to speak sometime this week. In commodities, oil and gold prices held steady, while London copper prices inched up. Canada's commodity-linked main stock index fell on Wednesday as lower oil prices weighed on energy shares. FOR CANADIAN MARKETS NEWS, CLICK ON CODES: TSX market report Canadian dollar and bonds report CA/ Reuters global stocks poll for Canada , Canadian markets directory
The Independent
35 minutes ago
- The Independent
Gillette maker Procter & Gamble to cut 7,000 jobs in two-year overhaul
The company behind Gillette and Pampers has announced plans to cut up to 7,000 jobs over the next two years as part of a restructuring programme. US-based Procter & Gamble (P&G) unveiled the plans during a strategy update on Thursday. The multinational manufacturing giant said it would be reducing its current non-manufacturing workforce by about 15%. The 7,000 affected roles represent about 6% of its total workforce. The two-year restructuring programme will help it make changes resulting in 'efficiencies, faster innovation, and cost reduction', according to the firm. P&G did not specify which roles will be affected or where they will be based. The Ohio-based company hired about 108,000 employees at the end of June last year. Around half of those were in manufacturing roles, and more than a quarter were based in the US. It makes a range of household brands including Ariel, Oral-B, Always and Tampax, and hair care brands Head & Shoulders and Herbal Essences. P&G recently said it was exposed to risks in the global economic environment, including new and increased tariffs, particularly between the US and China. This is because its products are sold in countries around the world so it is likely to be affected by increased costs for importing goods. It has said it could continue to raise prices on some brands to mitigate the impact of cost increases, which it admitted could have a knock-on effect on demand and sales.
The Guardian
36 minutes ago
- The Guardian
Millions in west do not know they have aggressive fatty liver disease, study says
More than 15 million people in the US, UK, Germany and France do not know they have the most aggressive form of fatty liver disease, according to research. Metabolic dysfunction-associated steatotic liver disease (MASLD) – the formal name for non-alcoholic fatty liver disease – occurs in people who drink no or minimal amounts of alcohol whose liver contains more than 5% fat. Around two-thirds of patients with type 2 diabetes are thought to have the condition, which is also associated with obesity, heart and circulatory disease. Around 5% of adults globally have the most aggressive form of MASLD. Metabolic dysfunction-associated steatohepatitis (MASH) causes fibrosis (scarring) and can lead to cirrhosis and is linked to greater risk of cardiovascular disease, chronic kidney disease and liver cancer. But the vast majority of people do not know they have the condition. An international group of researchers examined prevalence and diagnosis of aggressive fatty liver disease in the US, UK, Germany and France. The researchers found that just under 3% of people in the UK, France and Germany, and 4% of those in the US have MASH, but diagnosis rates were below 18%. That means about 20 million people in the US, UK, Germany and France are living with MASH but only 2.5 million people have a diagnosis, leaving more than three-quarters – about 16.7 million people – unaware they have the condition. The report, published in the Lancet Regional Health Europe and presented at an the meeting of the global thinktank on steatotic liver disease in Barcelona, Spain on Thursday, calls for a doubling in diagnosis rates from 2022 levels. Traditionally, MASH was diagnosed through biopsy, but now non-invasive methods, such as blood tests, ultrasound and MRI scans can be used. As a result, everyone with type 2 diabetes; obesity combined with one or more other risk factors; and those with persistently high liver enzymes should be screened for MASH, the researchers conclude. Dr Jeffrey Lazarus, the lead author of the paper and a professor of global health in New York and Barcelona, said: 'Undiagnosed MASH costs economies billions of pounds in lost productivity and poor health. Unless diagnosis rates are doubled, alongside similar increases in treatment and care, direct health costs alone are predicted to triple over the next 20 years.' Responding to the findings, Emmanouil Tsochatzis, a professor of hepatology at UCL and a consultant hepatologist at the Royal Free hospital, said: 'More than 15 million people across the US and Europe have the deadliest form of fatty liver disease – and don't know it. Without faster diagnosis and access to treatment, the human and economic toll will skyrocket.' The research has also prompted renewed calls for weight loss jabs to be used to treat MASH. Dr Paul Brennan, a co-author of the Lancet paper and a hepatologist at NHS Tayside, said: 'GLP-1s (including Wegovy and Mounjaro) offer the potential to resynchronise our metabolism, by introducing feelings of satiety – fullness – and delaying the time the stomach takes to empty. These effects often result in reduced calorie intake, and improvements in how the liver handles nutrients as a result of weight loss, thus reducing scar tissue formation in the liver.' Michael Betel, the president of the Fatty Liver Alliance, said: 'Too many people living with type 2 diabetes or obesity are never tested for MASH until it's too late. We need a huge increase in liver health assessments in patients living with these diseases, alongside lifestyle changes and for some, when appropriate, weight loss drugs to reduce blood sugar and appetite. While weight loss drugs weren't created to treat liver disease, trials suggest they could benefit multiple metabolic-related conditions, and improve our liver health.' Separately a study published on Wednesday found that the diabetes drug dapagliflozin, which reduces blood sugar levels, can also reduce fat levels and fibrosis in the liver.
